Abstract
Purpose
Telomerase reverse transcriptase promoter mutations are found in highly aggressive thyroid malignancies. Our aim was to define the ultrasonographic features of telomerase reverse transcriptase promoter-mutated papillary thyroid cancer and to evaluate their predictive performances.
Methods
Ultrasonographic findings were reviewed for 185 patients with surgically confirmed papillary thyroid cancer between 1994 and 2004. Genomic DNA to identify telomerase reverse transcriptase promoter mutations was extracted from archived surgical specimens. Logistic regression analysis was performed to compare clinical factors and ultrasonographic findings between telomerase reverse transcriptase promoter-mutated and wild-type papillary thyroid cancers.
Results
A telomerase reverse transcriptase promoter mutation was detected in 8.1% (15 of 185) of specimens from papillary thyroid cancer patients with a strong trend toward increasing age. Nonparallel orientation and microlobulated margin were independent ultrasonographic findings for predicting telomerase reverse transcriptase promoter-mutated papillary thyroid cancer in patients over 50 years (odds ratio 5.898, 95% confidence interval 1.092–31.851, P = 0.039 for orientation; odds ratio 5.813, 95% confidence interval 1.320–25.602, P = 0.020 for margin). Prevalence of telomerase reverse transcriptase promoter mutations increased to 50.0% in papillary thyroid cancer patients older than 50 years with both ultrasonographic findings and was 0% in patients without either finding. For identifying telomerase reverse transcriptase promoter-mutated papillary thyroid cancer, ultrasonographic had 64.3% sensitivity, 80.8% specificity, 50.0% positive predictive value and 88.4% negative predictive value.
Conclusions
Telomerase reverse transcriptase promoter-mutated papillary thyroid cancer could be suggested by the ultrasonographic features of nonparallel orientation and microlobulated margin in patients older than 50 years. Prebiopsy recognition of this unique ultrasonographic pattern would mandate the nodule fall into a “biopsy suggested” category.
Similar content being viewed by others
References
R. Liu, M. Xing, TERT promoter mutations in thyroid cancer. Endocr. Relat. Cancer 23, R143–R155 (2016)
T.H. Kim, Y.E. Kim, S. Ahn, J.Y. Kim, C.S. Ki, Y.L. Oh, K. Kim, J.W. Yun, W.Y. Park, J.H. Choe, J.H. Kim, J.S. Kim, S.W. Kim, J.H. Chung, TERT promoter mutations and long-term survival in patients with thyroid cancer. Endocr. Relat. Cancer 23, 813–823 (2016)
B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G.W. Randolph, A.M. Sawka, M. Schlumberger, K.G. Schuff, S.I. Sherman, J.A. Sosa, D.L. Steward, R.M. Tuttle, L. Wartofsky, 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26, 1–133 (2016)
D. de Biase, G. Gandolfi, M. Ragazzi, M. Eszlinger, V. Sancisi, M. Gugnoni, M. Visani, A. Pession, G. Casadei, C. Durante, G. Costante, R. Bruno, M. Torlontano, R. Paschke, S. Filetti, S. Piana, A. Frasoldati, G. Tallini, A. Ciarrocchi, TERT promoter mutations in papillary thyroid microcarcinomas. Thyroid 25, 1013–1019 (2015)
Cancer Genome Atlas Research Network, Integrated genomic characterization of papillary thyroid carcinoma. Cell 159, 676–690 (2014)
S.Y. Nam, J.H. Shin, B.K. Han, E.Y. Ko, E.S. Ko, S.Y. Hahn, J.H. Chung, Preoperative ultrasonographic features of papillary thyroid carcinoma predict biological behavior. J. Clin. Endocrinol. Metab. 98, 1476–1482 (2013)
T. Uematsu, M. Kasami, S. Yuen, Triple-negative breast cancer: correlation between MR imaging and pathologic findings. Radiology 250, 638–647 (2009)
J.H. Shin, J.H. Baek, J. Chung, E.J. Ha, J.H. Kim, Y.H. Lee, H.K. Lim, W.J. Moon, D.G. Na, J.S. Park, Y.J. Choi, S.Y. Hahn, S.J. Jeon, S.L. Jung, D.W. Kim, E.K. Kim, J.Y. Kwak, C.Y. Lee, H.J. Lee, J.H. Lee, J.H. Lee, K.H. Lee, S.W. Park, J.Y. Sung, R. Korean society of thyroid, R. Korean society of, ultrasonography diagnosis and imaging-based management of thyroid nodules: revised Korean society of thyroid radiology consensus statement and recommendations. Korean J. Radiol. 17, 370–395 (2016)
E.G. Grant, F.N. Tessler, J.K. Hoang, J.E. Langer, M.D. Beland, L.L. Berland, J.J. Cronan, T.S. Desser, M.C. Frates, U.M. Hamper, W.D. Middleton, C.C. Reading, L.M. Scoutt, A.T. Stavros, S.A. Teefey, Thyroid ultrasound reporting lexicon: white paper of the ACR thyroid imaging, reporting and data system (TIRADS) committee. J. Am. Coll. Radiol. 12, 1272–1279 (2015)
S. Kim, J. Lee, M.E. Hong, I.G. Do, S.Y. Kang, S.Y. Ha, S.T. Kim, S.H. Park, W.K. Kang, M.G. Choi, J.H. Lee, T.S. Sohn, J.M. Bae, S. Kim, D.H. Kim, K.M. Kim, High-throughput sequencing and copy number variation detection using formalin fixed embedded tissue in metastatic gastric cancer. PLoS ONE 9, e111693 (2014)
S. Horn, A. Figl, P.S. Rachakonda, C. Fischer, A. Sucker, A. Gast, S. Kadel, I. Moll, E. Nagore, K. Hemminki, D. Schadendorf, R. Kumar, TERT promoter mutations in familial and sporadic melanoma. Science 339, 959–961 (2013)
K. Barnett, S.W. Mercer, M. Norbury, G. Watt, S. Wyke, B. Guthrie, Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 380, 37–43 (2012)
G. Lyratzopoulos, P. Vedsted, H. Singh, Understanding missed opportunities for more timely diagnosis of cancer in symptomatic patients after presentation. Br. J. Cancer 112(Suppl 1), S84–S91 (2015)
H.S. Ahn, H.G. Welch, South Korea’s thyroid-cancer “Epidemic”--turning the tide. N. Engl. J. Med. 373, 2389–2390 (2015)
L.J. Esserman, I.M. Thompson Jr., B. Reid, Overdiagnosis and overtreatment in cancer: an opportunity for improvement. J. Am. Med. Assoc. 310, 797–798 (2013)
H.G. Welch, W.C. Black, Overdiagnosis in cancer. J. Natl. Cancer Inst. 102, 605–613 (2010)
M. Xing, A.S. Alzahrani, K.A. Carson, D. Viola, R. Elisei, B. Bendlova, L. Yip, C. Mian, F. Vianello, R.M. Tuttle, E. Robenshtok, J.A. Fagin, E. Puxeddu, L. Fugazzola, A. Czarniecka, B. Jarzab, C.J. O’Neill, M.S. Sywak, A.K. Lam, G. Riesco-Eizaguirre, P. Santisteban, H. Nakayama, R.P. Tufano, S.I. Pai, M.A. Zeiger, W.H. Westra, D.P. Clark, R. Clifton-Bligh, D. Sidransky, P.W. Ladenson, V. Sykorova, Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. J. Am. Med. Assoc. 309, 1493–1501 (2013)
T.H. Kim, Y.J. Park, J.A. Lim, H.Y. Ahn, E.K. Lee, Y.J. Lee, K.W. Kim, S.K. Hahn, Y.K. Youn, K.H. Kim, B.Y. Cho, J. Park do, The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 118, 1764–1773 (2012)
J.Y. Kwak, E.K. Kim, W.Y. Chung, H.J. Moon, M.J. Kim, J.R. Choi, Association of BRAFV600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma. Radiology 253, 854–860 (2009)
J. Hwang, J.H. Shin, B.K. Han, E.Y. Ko, S.S. Kang, J.W. Kim, J.H. Chung, Papillary thyroid carcinoma with BRAFV600E mutation: sonographic prediction. Am. J. Roentgenol. 194, W425–W430 (2010)
F.W. Huang, E. Hodis, M.J. Xu, G.V. Kryukov, L. Chin, L.A. Garraway, Highly recurrent TERT promoter mutations in human melanoma. Science 339, 957–959 (2013)
Z. Liu, Q. Li, K. Li, L. Chen, W. Li, M. Hou, T. Liu, J. Yang, C. Lindvall, M. Bjorkholm, J. Jia, D. Xu, Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells. Oncogene 32, 4203–4213 (2013)
D.G. Na, J.H. Baek, J.Y. Sung, J.H. Kim, J.K. Kim, Y.J. Choi, H. Seo, Thyroid imaging reporting and data system risk stratification of thyroid nodules: categorization based on solidity and echogenicity. Thyroid 26, 562–572 (2016)
W.J. Moon, S.L. Jung, J.H. Lee, D.G. Na, J.H. Baek, Y.H. Lee, J. Kim, H.S. Kim, J.S. Byun, D.H. Lee, Benign and malignant thyroid nodules: US differentiation--multicenter retrospective study. Radiology 247, 762–770 (2008)
A. Jalaguier-Coudray, J. Thomassin-Piana, Solid masses: what are the underlying histopathological lesions? Diagn. Interv. Imaging 95, 153–168 (2014)
P.M. Lamb, N.M. Perry, S.J. Vinnicombe, C.A. Wells, Correlation between ultrasound characteristics, mammographic findings and histological grade in patients with invasive ductal carcinoma of the breast. Clin. Radiol. 55, 40–44 (2000)
E.K. Kim, C.S. Park, W.Y. Chung, K.K. Oh, D.I. Kim, J.T. Lee, H.S. Yoo, New sonographic criteria for recommending fine-needle aspiration biopsy of nonpalpable solid nodules of the thyroid. Am. J. Roentgenol. 178, 687–691 (2002)
National Comprehensive Cancer Network. Thyroid carcinoma (Version 1.2016). http://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf. Accessed 22 March 2017.
Funding
This research was supported by Korean Foundation for Cancer Research grant CB-2011-03-02 (to JHC). The funders were not involved in the study design, conduct, or manuscript preparation.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Individual written consent was waived by the committee given the lack of intervention and reporting of data in an individually non-identifiable way.
Additional information
Tae Hyuk Kim and Chang-Seok Ki contributed equally to this work.
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Kim, T.H., Ki, CS., Hahn, S.Y. et al. Ultrasonographic prediction of highly aggressive telomerase reverse transcriptase (TERT) promoter-mutated papillary thyroid cancer. Endocrine 57, 234–240 (2017). https://doi.org/10.1007/s12020-017-1340-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-017-1340-3